Abstract
Background: Many studies have shown that the reduction of low density lipoprotein (LDLC) levels provides cardiovascular protection; therefore LDL-C is considered to be a core therapeutic target in anti-hyperlipidaemia treatment. However, the LDL-C goal attainment is often not satisfied in China with conventional lipid-lowering agents. Many patients seek help from Chinese Herbal Medicine (CHM). To further understand the current use of CHM in hyperlipidaemia, we conducted a review based on a systematic literature search and data mining.
Methods: We comprehensively searched MEDLINE, EBSCO, Cochrane Library, EMBASE, Chinese Biomedical Literature Database (CBM), Chinese Scientific Journal Database (VIP), China National Knowledge Infrastructure (CNKI) and Wanfang database to identify potentially relevant articles. We included literatures that met the following criteria: (1) randomized or non-randomized controlled trials; (2) observational clinical trials; (3) case series or case reports. In order to enrich the systematic literature searching and provide the quantitative relationship between relative items and the treatment of hyperlipidaemia, the data mining was also conducted by filtering the biomedical literature on hyperlipidaemia in SinoMed and other available databases like VIP and CNKI.
Results: In summary, 282 records of CHM on hyperlipidaemia were captured and analysed. The top used single herb was Radix Salviae Miltiorrhizae. The most frequently used formula was Xuefuzhuyu Decoction. The most used herbs in clinical practice have some pharmacological evidences. The mechanisms are different, but could be classified into three categories: inhibiting synthesis, increasing decomposition and reducing absorption.
Conclusion: CHM shows positive effect in the treatment of hyperlipidaemia and has the potential to be used in combination with conventional drugs. However, their use should be demonstrated in highquality clinical trials and clinicians should pay attention to potential herb-drug interactions.
Keywords: Hyperlipidaemia, chinese herbal medicine, traditional chinese medicine, pharmacological mechanism, data mining, CNKI.
Graphical Abstract
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
Related Journals
Current Drug Safety
Current Cardiology Reviews
Cardiovascular & Hematological Agents in Medicinal Chemistry
Current Hypertension Reviews
Cardiovascular & Hematological Disorders-Drug Targets
Current Neuropharmacology
Current Pharmaceutical Design
Current Pharmaceutical Analysis
CNS & Neurological Disorders - Drug Targets
Current Molecular Pharmacology
Related Books
New Findings from Natural Substances
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Herbal Medicine: Back to the Future
Cardiac Care and COVID-19: Perspectives in Medical Practice
Nanomedicinal Approaches Towards Cardiovascular Disease
Postbiotics: Science, Technology and Applications
62
5
1
1